- Home
- CEE vs ELUT Comparison
CEE vs ELUT Comparison
Compare CEE & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- ELUT
- Stock Information
- Founded
- CEE 1990
- ELUT 2015
- Country
- CEE Germany
- ELUT United States
- Employees
- CEE N/A
- ELUT N/A
- Industry
- CEE Finance Companies
- ELUT Medical Specialities
- Sector
- CEE Finance
- ELUT Health Care
- Exchange
- CEE Nasdaq
- ELUT Nasdaq
- Market Cap
- CEE 83.8M
- ELUT 94.0M
- IPO Year
- CEE N/A
- ELUT 2020
- Fundamental
- Price
- CEE $15.48
- ELUT $1.72
- Analyst Decision
- CEE
- ELUT Strong Buy
- Analyst Count
- CEE 0
- ELUT 2
- Target Price
- CEE N/A
- ELUT $8.00
- AVG Volume (30 Days)
- CEE 22.0K
- ELUT 40.6K
- Earning Date
- CEE 01-01-0001
- ELUT 05-08-2025
- Dividend Yield
- CEE 3.86%
- ELUT N/A
- EPS Growth
- CEE N/A
- ELUT N/A
- EPS
- CEE N/A
- ELUT N/A
- Revenue
- CEE N/A
- ELUT $23,711,000.00
- Revenue This Year
- CEE N/A
- ELUT $37.67
- Revenue Next Year
- CEE N/A
- ELUT $63.22
- P/E Ratio
- CEE N/A
- ELUT N/A
- Revenue Growth
- CEE N/A
- ELUT N/A
- 52 Week Low
- CEE $7.80
- ELUT $1.69
- 52 Week High
- CEE $10.32
- ELUT $5.24
- Technical
- Relative Strength Index (RSI)
- CEE 63.77
- ELUT 35.28
- Support Level
- CEE $15.32
- ELUT $1.68
- Resistance Level
- CEE $15.74
- ELUT $2.09
- Average True Range (ATR)
- CEE 0.33
- ELUT 0.20
- MACD
- CEE 0.08
- ELUT -0.01
- Stochastic Oscillator
- CEE 78.63
- ELUT 5.26
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.